Detailed description page of ThPDB2

This page displays user query in tabular form.

Th1020 details
Primary information
ID10142
Therapeutic IDTh1020
Protein NameAsparaginase
Sequence>Th1020_Asparaginase MEFFKKTALAALVMGFSGAALALPNITILATGGTIAGGGDSATKSNYTVGKVGVENLVNAVPQLKDIANVKGEQVVNIGSQDMNDNVWLTLAKKINTDCDKTDGFVITHGTDTMEETAYFLDLTVKCDKPVVMVGAMRPSTSMSADGPFNLYNAVVTAADKASANRGVLVVMNDTVLDGRDVTKTNTTDVATFKSVNYGPLGYIHNGKIDYQRTPARKHTSDTPFDVSKLNELPKVGIVYNYANASDLPAKALVDAGYDGIVSAGVGNGNLYKSVFDTLATAAKTGTAVVRSSRVPTGATTQDAEVDDAKYGFVASGTLNPQKARVLLQLALTQTKDPQQIQQIFNQY
Molecular Weight31731.9
Chemical FormulaC1377H2208N382O442S17
Isoelectric Point4.67
Hydrophobicity0.059
Melting pointNA
Half-life8-30 hours
DescriptionL-asparagine amidohydrolase from E. coli
Indication/DiseaseTo treat acute lympocytic leukemia and non-Hodgkins lymphoma
PharmacodynamicsIn most patients with acute leukemia, the malignant cells are dependent on an exogenous source of asparagine for survival. Normal cells, however, are able to synthesize asparagine and thus are affected less by the rapid depletion produced by treatment with the enzyme asparaginase. Elspar exploits a metabolic defect in asparagine synthesis of some malignant cells.
Mechanism of ActionAsparaginase converts asparagine to aspartic acid and ammonia. It facilitates production of oxalo-acetate which is needed for general cellular metabolism. Some malignant cells lose the ability to produce asparagine and thus the loss of exogenous sources of asparagine leads to cell death.
ToxicityNA
MetabolismNA
AbsorptionNA
Apparent volume of distribution was slightly greater than the plasma volume. Asparaginase levels in cerebrospinal fluid were less than 1% of concurrent plasma levels
ClearanceNA
CategoriesAmidohydrolases, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Asparaginase, Asparagine-specific Enzyme, Enzymes, Enzymes and Coenzymes, Hydrolases, Narrow Therapeutic Index Drugs, Thyroxine-binding globulin inhibitors
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
TargetL-asparagine
Brand NameElspar
CompanyLundbeck Inc.
Brand DescriptionLundbeck Inc.
Prescribed ForTo treat acute lymphocytic leukemia. It is used along with other cancer medicines. Elspar is an antineoplastic agent that works by decreasing the amount of asparagine in the body, which kills certain leukemia cells
Chemical NameNA
FormulationEach vial contains 10,000 International Units of asparaginase and 80 mg of mannitol.
Physical Appearance Lyophilized plug or powder
Route of AdministrationIntravenous or intramuSubcutaneousular. Intravenou
Recommended DosageThe recommended dose of Elspar is 6,000 International Units/m_ intramuscularly (IM) or intravenously (IV) three times a week.
ContraindicationAllergic
Side EffectsFever, chills (see flu like symptoms), Nausea and vomiting, Allergic reaction, (sudden onset of wheezing, itching, rash, face swelling, agitation, low blood pressure). You will be monitored closely for this reaction, Poor appetite, Stomach cramping
Useful Link 1Link
Useful Link 2NA
RemarksNA


Primary information
ID10143
Therapeutic IDTh1020
Protein NameAsparaginase
Sequence>Th1020_Asparaginase MEFFKKTALAALVMGFSGAALALPNITILATGGTIAGGGDSATKSNYTVGKVGVENLVNAVPQLKDIANVKGEQVVNIGSQDMNDNVWLTLAKKINTDCDKTDGFVITHGTDTMEETAYFLDLTVKCDKPVVMVGAMRPSTSMSADGPFNLYNAVVTAADKASANRGVLVVMNDTVLDGRDVTKTNTTDVATFKSVNYGPLGYIHNGKIDYQRTPARKHTSDTPFDVSKLNELPKVGIVYNYANASDLPAKALVDAGYDGIVSAGVGNGNLYKSVFDTLATAAKTGTAVVRSSRVPTGATTQDAEVDDAKYGFVASGTLNPQKARVLLQLALTQTKDPQQIQQIFNQY
Molecular Weight31731.9
Chemical FormulaC1377H2208N382O442S17
Isoelectric Point4.67
Hydrophobicity0.059
Melting pointNA
Half-life8-30 hours
DescriptionL-asparagine amidohydrolase from E. coli
Indication/DiseaseTo treat acute lympocytic leukemia and non-Hodgkins lymphoma
PharmacodynamicsIn most patients with acute leukemia, the malignant cells are dependent on an exogenous source of asparagine for survival. Normal cells, however, are able to synthesize asparagine and thus are affected less by the rapid depletion produced by treatment with the enzyme asparaginase. Elspar exploits a metabolic defect in asparagine synthesis of some malignant cells.
Mechanism of ActionAsparaginase converts asparagine to aspartic acid and ammonia. It facilitates production of oxalo-acetate which is needed for general cellular metabolism. Some malignant cells lose the ability to produce asparagine and thus the loss of exogenous sources of asparagine leads to cell death.
ToxicityNA
MetabolismNA
AbsorptionNA
Apparent volume of distribution was slightly greater than the plasma volume. Asparaginase levels in cerebrospinal fluid were less than 1% of concurrent plasma levels
ClearanceNA
CategoriesAmidohydrolases, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Asparaginase, Asparagine-specific Enzyme, Enzymes, Enzymes and Coenzymes, Hydrolases, Narrow Therapeutic Index Drugs, Thyroxine-binding globulin inhibitors
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Brand NameKidrolase
CompanyJazz Pharmaceuticals France Sas
Brand DescriptionJazz Pharmaceuticals France Sas
Prescribed ForNA
Chemical NameNA
FormulationNA
Physical Appearance NA
Route of AdministrationNA
Recommended DosageNA
ContraindicationNA
Side EffectsMouth sores, Pancreatitis (inflammation of the pancreas) in up to 10% of patients. Mainly noted in blood tests that return to normal after therapy is discontinued. Rarely may be severe causing symptoms. Symptoms of acute pancreatitis include: (pain in the upper abdomen that worsens with eating, swollen and tender abdomen, nausea, vomiting, fever, and rapid pulse).
Useful Link 1Link
Useful Link 2NA
RemarksNA


Primary information
ID10144
Therapeutic IDTh1020
Protein NameAsparaginase
Sequence>Th1020_Asparaginase MEFFKKTALAALVMGFSGAALALPNITILATGGTIAGGGDSATKSNYTVGKVGVENLVNAVPQLKDIANVKGEQVVNIGSQDMNDNVWLTLAKKINTDCDKTDGFVITHGTDTMEETAYFLDLTVKCDKPVVMVGAMRPSTSMSADGPFNLYNAVVTAADKASANRGVLVVMNDTVLDGRDVTKTNTTDVATFKSVNYGPLGYIHNGKIDYQRTPARKHTSDTPFDVSKLNELPKVGIVYNYANASDLPAKALVDAGYDGIVSAGVGNGNLYKSVFDTLATAAKTGTAVVRSSRVPTGATTQDAEVDDAKYGFVASGTLNPQKARVLLQLALTQTKDPQQIQQIFNQY
Molecular Weight31731.9
Chemical FormulaC1377H2208N382O442S17
Isoelectric Point4.67
Hydrophobicity0.059
Melting pointNA
Half-life8-30 hours
DescriptionL-asparagine amidohydrolase from E. coli
Indication/DiseaseTo treat acute lympocytic leukemia and non-Hodgkins lymphoma
PharmacodynamicsIn most patients with acute leukemia, the malignant cells are dependent on an exogenous source of asparagine for survival. Normal cells, however, are able to synthesize asparagine and thus are affected less by the rapid depletion produced by treatment with the enzyme asparaginase. Elspar exploits a metabolic defect in asparagine synthesis of some malignant cells.
Mechanism of ActionAsparaginase converts asparagine to aspartic acid and ammonia. It facilitates production of oxalo-acetate which is needed for general cellular metabolism. Some malignant cells lose the ability to produce asparagine and thus the loss of exogenous sources of asparagine leads to cell death.
ToxicityNA
MetabolismNA
AbsorptionNA
Apparent volume of distribution was slightly greater than the plasma volume. Asparaginase levels in cerebrospinal fluid were less than 1% of concurrent plasma levels
ClearanceNA
CategoriesAmidohydrolases, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Asparaginase, Asparagine-specific Enzyme, Enzymes, Enzymes and Coenzymes, Hydrolases, Narrow Therapeutic Index Drugs, Thyroxine-binding globulin inhibitors
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Brand NameRylaze, Spectrila
CompanyJazz Pharmaceuticals, Inc., Medac Gesellschaft Fuer Klinische Spezialpraeparate Mb H
Brand DescriptionJazz Pharmaceuticals, Inc., Medac Gesellschaft Fuer Klinische Spezialpraeparate Mb H
Prescribed ForNA
Chemical NameNA
FormulationNA
Physical Appearance NA
Route of AdministrationNA
Recommended DosageNA
ContraindicationNA
Side EffectsCentral neurotoxicity: excessive sleepiness, depression, hallucinations, agitation, disorientation or seizure, stupor, confusion and/or coma.
Useful Link 1Link
Useful Link 2NA
RemarksNA